Clinical Efficacy of Miramistin in Children with Exacerbation of Chronic Fungal Adenoiditis
To assess clinical efficacy of Miramistin in children with exacerbation of chronic fungal adenoiditis we examined 343 children aged from 3 to 14 years. 64 (18.7%) children had fungal infection and received Miramistin and/or systemic antifungal therapy. The study showed that Miramistin could be used as monotherapy or as a part of combination therapy in children with exacerbation of chronic fungal adenoiditis. Miramistin relieved the main symptoms of the disease and allowed to preserve pharyngeal tonsil in 74.5% of children.